Phthisis Diagnostics founder Eric Houpt with Crystal Icenhour, president and director of research. We are spotlighting Phthisis as they graduate from the T100 program. We wish them continued success!
Read More >>
T100 Spotlight Archive >> |
|
Under the direction of the VP for Research, the T100 Alumni Mentoring Program offers U.Va alumni the opportunity to guide start-up companies that have research origins at the University. T100 members provide hands-on mentoring and financial contributions to support companies as they evolve from concept to commercial enterprise. Team members participate in a monthly conference call to help advance the commercial promise of the technology.
JOIN T100 Interested alumni are encouraged to inquire about mentorship opportunities. Faculty entrepreneurs should contact us to find out how T100 can support commercializable technologies. Find out more.
TAU THERAPEUTICS ADVANCES BRAIN CANCER TREATMENTS (10.3.09) Tau has developed a drug treatment that may stop brain cancer growth while reducing the side effects of chemotherapy.
BETTER WORLD REPORT FEATURES T100 COMPANIES (6.29.09) The Association of University Technology Managers (AUTM) highlights T100 graduate companies ContraVac and PluroGen in its 2009 Better World Report. The report focuses on academic technologies that are having a positive effect on global health.
PLUROGEN MAKES COMMERCIAL ADVANCES (6.15.09) Licensing agreements and research collaborations are helping PluroGen advance its PluroGel technology.
T100 COMPANIES RECOGNIZED AS INNOVATION LEADERS (5.22.09) The Charlottesville Business Innovation Council (CBIC) awarded its Breakthrough award to T100 graduate, PluroGen Therapeutics, and recognized T100 company, Tau Therapeutics, as a finalist.
FOUNDER OF GLOBAL CELL SOLUTIONS RECEIVES 2009 ENGELBERGER AWARD IN LEADERSHIP (4.8.09) Robin Felder received the Robotics Award for Leadership, the highest recognition given by the Robotics Industries Association (RIA). Felder's robotics innovations are the foundation of T100 graduate company, Global Cell Solutions.
ADVANCES MADE IN TYPE 2 DIABETES TREATMENT (1.22.09) Results of a preclinical study involving DiaKine Therapeutics’ lead drug candidate Lisofylline indicate the compound may reduce two key risk factors for type 2 diabetes.
T100 COMPANY RECEIVES FDA APPROVAL TO TREAT PANCREATIC CANCER (12.17.08) Tau Therapeutics has been granted orphan drug status to pursue its pancreatic cancer treatment using the T-channel-blocking drug mibefradil.
HEMOSONICS SELECTED AS FINALIST IN SE BIO SHOOT-OUT (12.16.08) T100 company, HemoSonics, was selected as one of the best new initial investment opportunities at the recent SE Bio Annual Investor Forum Early-Stage Shoot-out.
READ MORE T100 NEWS |
